Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
Beta Bionics, Inc. (BBNX)
Company Research
Source: GlobeNewswire
IRVINE, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2026 and raised its full year guidance for the year ending December 31, 2026. First Quarter 2026 Financial Highlights & Key Metrics Net sales of $27.6 million, up 57% compared to $17.6 million in the first quarter of 2025. Durable Medical Equipment (DME) channel net sales of $16.9 million, up 22% compared to $13.8 million in the first quarter of 2025.Pharmacy Benefit Plan (PBP) channel net sales of $10.7 million, up 181% compared to $3.8 million in the first quarter of 2025. Gross margin of 59.5%, up 864 basis points compared to 50.9% in the first quarter of 2025.New patient starts declined by at least 10% but less than 20% sequentially versus the fourth quarter of 2025. 70% of new patient starts came from multiple daily injections (MDI).High 30s p
Show less
Read more
Impact Snapshot
Event Time:
BBNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBNX alerts
High impacting Beta Bionics, Inc. news events
Weekly update
A roundup of the hottest topics
BBNX
News
- Beta Bionics (BBNX) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d-)" to "sell (e+)".MarketBeat
- Beta Bionics (BBNX) had its price target lowered by Leerink Partners from $25.00 to $24.00. They now have an "outperform" rating on the stock.MarketBeat
- Beta Bionics (BBNX) had its price target lowered by Stifel Nicolaus from $22.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5% [Seeking Alpha]Seeking Alpha
- Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
BBNX
Earnings
- 4/21/26 - Beat
BBNX
Sec Filings
- 4/21/26 - Form 10-Q
- 4/21/26 - Form 8-K
- 4/10/26 - Form ARS
- BBNX's page on the SEC website